• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 5:10:20 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $INMD alert in real time by email
    SC 13G/A 1 tm215949d2_sc13ga.htm SC 13G/A

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C.  20549

     

    SCHEDULE 13G/A 

    (Amendment No. 1)*

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

     

    InMode Ltd.
    (Name of Issuer)

     

    Ordinary shares, par value NIS 0.01 per share
    (Title of Class of Securities)

     

    M5425M 103
    (CUSIP Number)

     

    December 31, 2020
    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)

     

      ¨ Rule 13d-1(c)

     

      x Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP NO. M5425M 103 13G/A Page 2 of  11 Pages

     

    1 NAMES OF REPORTING PERSONS
    Israel Healthcare Ventures 2 L.P.
    2  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)  ¨
    (b)  x
    3 SEC USE ONLY
     
     
    4  CITIZENSHIP OR PLACE OF ORGANIZATION
    Island of Guernsey
     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    249,610
       
    7 SOLE DISPOSITIVE POWER
    0
       
    8 SHARED DISPOSITIVE POWER
    249,610

    9  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    249,610
     
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
    ¨
     
    11  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    Less than 1%**
     
    12 TYPE OF REPORTING PERSON*
    PN

     

    *See Item 4.

     

    **Based on 32,799,082 ordinary shares, par value NIS 0.01 per share (the “Ordinary Shares”) of the issuer outstanding as of December 31, 2019, based on information set forth in the Form 20-F filed by the issuer on February 18, 2020.

     

     

     

    CUSIP NO. M5425M 103 13G/A Page 3 of  11 Pages

     

    1 NAMES OF REPORTING PERSONS
    IHCV2 General Partner Limited
    2  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)  ¨
    (b)  x
    3 SEC USE ONLY
     
     
    4  CITIZENSHIP OR PLACE OF ORGANIZATION
    Island of Guernsey
     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    249,610
       
    7 SOLE DISPOSITIVE POWER
    0
       
    8 SHARED DISPOSITIVE POWER
    249,610

    9  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    249,610
     
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
    ¨
     
    11  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    Less than 1%**
     
    12 TYPE OF REPORTING PERSON*
    PN

     

    *See Item 4.

     

    ** Based on 32,799,082 ordinary shares, par value NIS 0.01 per share (the “Ordinary Shares”) of the issuer outstanding as of December 31, 2019, based on information set forth in the Form 20-F filed by the issuer on February 18, 2020.

     

     

     

     

    CUSIP NO. M5425M 103 13G/A Page 4 of  11 Pages

     

    1 NAMES OF REPORTING PERSONS
    Fort Limited
    2  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)  ¨
    (b)  x
    3 SEC USE ONLY
     
     
    4  CITIZENSHIP OR PLACE OF ORGANIZATION
    Island of Guernsey
     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
     
       
    7 SOLE DISPOSITIVE POWER
    0
       
    8 SHARED DISPOSITIVE POWER
    249,610

    9  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    249,610
     
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
    ¨
     
    11  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    Less than 1%**
     
    12 TYPE OF REPORTING PERSON*
    PN

     

    *See Item 4.

     

    ** Based on 32,799,082 ordinary shares, par value NIS 0.01 per share (the “Ordinary Shares”) of the issuer outstanding as of December 31, 2019, based on information set forth in the Form 20-F filed by the issuer on February 18, 2020.

     

     

     

     

    CUSIP NO. M5425M 103 13G/A Page 5 of  11 Pages

     

    1 NAMES OF REPORTING PERSONS
    Elton Limited
    2  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)  ¨
    (b)  x
    3 SEC USE ONLY
     
     
    4  CITIZENSHIP OR PLACE OF ORGANIZATION
    Island of Guernsey
     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    249,610
       
    7 SOLE DISPOSITIVE POWER
    0
       
    8 SHARED DISPOSITIVE POWER
    249,610

    9  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    249,610
     
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
    ¨
     
    11  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    Less than 1%**
     
    12 TYPE OF REPORTING PERSON*
    PN

     

    *See Item 4.

     

    ** Based on 32,799,082 ordinary shares, par value NIS 0.01 per share (the “Ordinary Shares”) of the issuer outstanding as of December 31, 2019, based on information set forth in the Form 20-F filed by the issuer on February 18, 2020.

     

     

     

     

    CUSIP NO. M5425M 103 13G/A Page 6 of  11 Pages

     

    1 NAMES OF REPORTING PERSONS
    Fort Management Services Limited
    2  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)  ¨
    (b)  x
    3 SEC USE ONLY
     
     
    4  CITIZENSHIP OR PLACE OF ORGANIZATION
    Island of Guernsey
     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    249,610
       
    7 SOLE DISPOSITIVE POWER
    0
       
    8 SHARED DISPOSITIVE POWER
    249,610

    9  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    249,610
     
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
    ¨
     
    11  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    Less than 1%**
     
    12 TYPE OF REPORTING PERSON*
    PN

     

    *See Item 4.

     

    ** Based on 32,799,082 ordinary shares, par value NIS 0.01 per share (the “Ordinary Shares”) of the issuer outstanding as of December 31, 2019, based on information set forth in the Form 20-F filed by the issuer on February 18, 2020.

     

     

     

     

    CUSIP NO. M5425M 103 13G/A Page 7 of  11 Pages

     

    1 NAMES OF REPORTING PERSONS
    Jos Ensink
    2  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)  ¨
    (b)  x
    3 SEC USE ONLY
     
     
    4  CITIZENSHIP OR PLACE OF ORGANIZATION
    Island of Guernsey
     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    249,610
       
    7 SOLE DISPOSITIVE POWER
    0
       
    8 SHARED DISPOSITIVE POWER
    249,610

     

    9  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    249,610
     
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
    ¨
     
    11  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    Less than 1% **
     
    12 TYPE OF REPORTING PERSON*
    PN

     

    *See Item 4.

     

    ** Based on 32,799,082 ordinary shares, par value NIS 0.01 per share (the “Ordinary Shares”) of the issuer outstanding as of December 31, 2019, based on information set forth in the Form 20-F filed by the issuer on February 18, 2020.

     

     

     

      

    Item 1

     

    (a) Name of Issuer:

     

    InMode Ltd.

     

    (b) Address of Issuer’s Principal Executive Offices:
     

    Tavor Building, Sha’ar Yokneam

    P.O. Box 533

    Yokneam 2069200, Israel

     

    Item 2

     

    (a) - (c) This Schedule 13G is being filed jointly by Israel HealthCare Ventures 2 L.P., a limited partnership registered under the laws of the Island of Guernsey (“IHCV 2”), IHCV2 General Partner Limited, a company incorporated under the laws of the Island of Guernsey (“IHCV2 GP”), Fort Limited, Elton Limited, and Fort Management Services Limited each a company incorporated under the laws of the Island of Guernsey, and Mr. Jos Ensink, each of whom is sometimes referred to herein as a “Reporting Person” and collectively as the “Reporting Persons”.

     

    The principal business address of each Reporting Person is Bordage House, Le Bordage, St Peter Port, Guernsey, GY 11BU.

     

    (d) Title of Class of Securities: Ordinary Shares
         
    (e) CUSIP Number: M5425M 103

     

    Item 3 Not applicable.

     

    Item 4 Ownership.

     

    See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Persons, which are incorporated herein.

     

    IHCV 2 beneficially owns 249,610 Ordinary Shares.

     

    IHCV2 GP is the general partner of IHCV 2. IHCV2 GP is controlled by its directors Fort Limited and Elton Limited. The controlling shareholder of Fort Limited and Elton Limited is Fort Management Services Limited. The controlling shareholder of Fort Management Services Limited is Mr. Jos Ensink. In such capacities, each of the foregoing Reporting Persons shares voting and dispositive power over, and may be deemed to beneficially own, 249,610 Ordinary Shares, but disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein.

     

    Item 5 Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  ☐

     

    Item 6 Ownership of More Than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Page 8 of 11 Pages

     

     

    Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8 Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9 Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10 Certification .

     

    Not applicable.

     

    Page 9 of 11 Pages 

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 12, 2021

     

      ISRAEL HEALTHCARE VENTURES 2 L.P.
      IHCV2 GENERAL PARTNER LIMITED
      FORT LIMITED
      ELTON LIMITED
      FORT MANAGEMENT SERVICES LIMITED
    JOS ENSINK
      BY: ISRAEL HEALTHCARE VENTURES 2 L.P.
      By:   IHCV2 General Partner Limited
         
      By: /s/ P.M Whitford
      Name: P.M. Whitford
      Title: Director
       
      For itself and on behalf of IHCV2 General Partner Limited, Fort Limited, Elton Limited Fort Management Services Limited and Jos. Ensink, pursuant to an agreement annexed as Exhibit 1 hereto.

     

    Page 10 of 11 Pages 

     

     

    Exhibit(s) :

     

    1 - Joint Filing Agreement

     

    Page 11 of 11 Pages

     

    Get the next $INMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INMD

    DatePrice TargetRatingAnalyst
    4/29/2025Buy → Neutral
    BTIG Research
    4/28/2025$22.00 → $16.00Outperform → Neutral
    Robert W. Baird
    10/17/2024$25.00Buy
    BTIG Research
    7/23/2024$21.00 → $19.00Buy → Hold
    Jefferies
    11/3/2023$52.00 → $24.00Buy → Neutral
    UBS
    10/13/2023$55.00 → $22.00Buy → Hold
    Canaccord Genuity
    3/29/2023$40.00Buy
    UBS
    2/17/2023Buy → Hold
    Needham
    More analyst ratings

    $INMD
    SEC Filings

    View All

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    11/5/25 7:00:08 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    9/18/25 7:30:09 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by InMode Ltd.

    6-K - InMode Ltd. (0001742692) (Filer)

    7/30/25 7:01:14 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins

    YOKNEAM, Israel, Nov. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights: Quarterly GAAP revenues of $93.2 million, compared to $130.2 million in the third quarter of 2024, which included $31.9 million of pre-order sales.Quarterly revenues from consumables and service of $19.9 million, an increase of 26% compared to the third quarter of 2024.GAAP operating income of $20.9 million. *Non-GAAP operating income was $23.6 million.Total cash position of $532.3 million as of September 30, 2025, incl

    11/5/25 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode Appoints Michael Dennison as President of North America

    IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.  Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar

    11/3/25 8:05:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Participate in Upcoming Investor Conferences

    YOKNEAM, Israel, Oct. 30, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation in the following investor conferences in November: UBS Global Healthcare Conference Presenter: Yair Malca, Chief Financial Officer Format: In-person one-on-one meetings Location: Palm Beach Gardens, FL When: Monday, November 10 Jefferies Global Healthcare Conference Presenter: Moshe Mizrahy, Chief Executive Officer Format: In-person fireside chat moderated by Matt Taylor, Senior Equity Analyst, and one-on-one meetings Location: London, U.K. When: Tuesday, November 18, Fireside Chat at 4:00 pm GMT A live webcast of the prese

    10/30/25 8:30:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InMode downgraded by BTIG Research

    BTIG Research downgraded InMode from Buy to Neutral

    4/29/25 8:06:22 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously

    4/28/25 1:56:11 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on InMode with a new price target

    BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00

    10/17/24 7:41:34 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Leadership Updates

    Live Leadership Updates

    View All

    InMode Appoints Michael Dennison as President of North America

    IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America.  Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at InMode, Dennison has advanced through roles from District Sales Manager to Vice President of Sales, driving national revenue growth, expanding market shar

    11/3/25 8:05:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Financials

    Live finance-specific insights

    View All

    InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins

    YOKNEAM, Israel, Nov. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights: Quarterly GAAP revenues of $93.2 million, compared to $130.2 million in the third quarter of 2024, which included $31.9 million of pre-order sales.Quarterly revenues from consumables and service of $19.9 million, an increase of 26% compared to the third quarter of 2024.GAAP operating income of $20.9 million. *Non-GAAP operating income was $23.6 million.Total cash position of $532.3 million as of September 30, 2025, incl

    11/5/25 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InMode to Report Third Quarter 2025 Financial Results and Hold Conference Call on November 5, Expects Q3 Revenue Between $92.5M-$93.0M, Reiterates FY 2025 Guidance Between $365M-$375M

    Conference call to be held on Wednesday, November 5, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 9, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter 2025 before the Nasdaq market opens on Wednesday, November 5, 2025. InMode is currently finalizing its financial results for the third quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and other developments that may aris

    10/9/25 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Return Capital to the Shareholders

    Believes the Board Should Approve and Execute a 10% Buyback in Q4 2025 and Another 10% Buyback in Q1 2026 Maintains Board Has Legal and Fiduciary Duty to Act in Best Interests of Shareholders  MIAMI, Sept. 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to return capital to shareholders.  The letter can be downloaded here The full text of the letter follows: September 9th, 2025 To the Board Members of InMode: In

    9/9/25 8:15:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $INMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:31:18 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

    SC 13G/A - InMode Ltd. (0001742692) (Subject)

    2/13/24 4:25:40 PM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by InMode Ltd.

    SC 13G - InMode Ltd. (0001742692) (Subject)

    2/6/24 9:36:39 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care